Sun Pharma share price declines ahead of Q4 results, dividend announcement; here's how company performed in Q3

The stock was trading at ₹1,885.70, reflecting a fall of 0.30%, on the National Stock Exchange (NSE) at 9:48 am. Its market capitalisation stands at ₹4,52,466.59 crore.

The stock had hit its 52-week high of ₹1,916.60 per share on May 11, 2026, while its 52-week low of ₹1,548 apiece was recorded on September 26, 2025.

The scrip has gained 0.40% in the past week and 12.94% in a month. Year-to-date, it has advanced 9.57%.

In an exchange filing, the firm said that its board will meet on May 22 to "consider and approve audited standalone and consolidated financial results for the quarter and year ended 31 March 2026."

The drugmaker will also consider and recommend a final dividend, if any, for the fiscal year 2026 for shareholders' approval at the ensuing annual general meeting (AGM).

How did Sun Pharma perform in Q3 FY26?

Sun Pharmaceutical Industries' consolidated profit after tax (PAT) advanced 16.03% to ₹3,368.81 crore in the third quarter of FY26, compared to ₹2,903.38 crore in the corresponding period of the previous fiscal year.

The consolidated revenue from operations climbed 13.49% to ₹15,520.54 crore in Q3 FY26 as against ₹13,675.46 crore in the final quarter of FY25.

The company's EBITDA (earnings before interest, tax, depreciation and amortisation) stood at ₹4,984.4 crore in the December quarter of FY26, showing an increase of 23.4% YoY from ₹4,009 crore in the year-ago period.